Prospectus - Jones & Bartlett Learning



Table of Contents x-ix

Preface xiv

Andrew R. Marks

Columbia University Colleges of Physicians and Surgeons, New York, USA.

PART 1 – CELL DEATH

1 Pharmacological manipulation of cell death: clinical applications in sight?

Guido Kroemer and Douglas Green

Center for National Scientific Research, Villejif Cedex, France.

2 Pharmacological manipulation of Bcl-2 family members to control cell death

Anthony G. Letai

Harvard University, Cambridge, Massachusetts, USA.

3 Caspases: Pharmacological manipulation of cell death

Inna N. Lavrik, Alexander Golks, and Peter H. Krammer

German Cancer Research Center, Heidelberg, Germany.

4 IKK/NF-(B signaling: balancing life and death– a new approach to cancer therapy

Jun-Li Luo, Hideaki Kamata, and Michael Karin

University of California, San Diego, La Jolla, California, USA.

5 Reawakening the cellular death program in neoplasia through

therapeutic blockade of IAP function

Casey W. Wright and Colin Duckett

University of Michigan, Ann Arbor, Michigan, USA.

6 The survival kinases Akt and Pim as potential pharmacologic targets

Ravi Amaravadi and Craig Thompson

University of Pennsylvania, Philadelphia, Pennsylvania, USA.

7 Mitochondria: pharmacological manipulation of cell death

Lisa Bouchier-Hayes, Lydia Lartigue, and Donald Newmeyer

La Jolla Institute for Allergies and Immunology, San Diego, California, USA.

8 Death versus survival: functional interaction between the apoptotic and

stress-inducible heat shock protein pathways

Helen M. Beere

La Jolla Institute for Allergies and Immunology, San Diego, California, USA.

9 Autophagy in cell death: an innocent convict?

Beth Levine and Junying Yuan

University of Texas Southwestern Medical Center, Dallas, Texas, USA.

10 Endoplasmic reticulum stress: cell life and death decisions

Chunyan Xu, Beatrice Bailly-Maitre, and John Reed

The Burnham Institute, La Jolla, California, USA.

PART 2 – ONCOLOGY

11 Dysregulation of Met receptor tyrosine kinase activity in invasive tumors

Alla Danilkovitch-Miagkova and Berton Zbar

National Cancer Institute, NIH, Bethesda, Maryland, USA.

12 Integrins in invasive growth

Cord Brakebusch, Daniel Bouvard, Fabio Stanchi, Takao Sakai, and Reinhard Fässler

Lund University, Lund, Sweden.

13 Stat proteins and oncogenesis

Jacqueline Bromberg

Memorial Sloan Kettering Cancer Center, New York, USA.

14 The cadherin-catenin adhesion system in signaling and cancer

Maralice Conacci-Sorrell, Jacob Zhurinsky, and Avri Ben-Ze’ev

Weismann Institute, Rehovot, Israel.

15 Do tumor-suppressive mechanisms contribute to organism aging by inducing

stem cell senescence?

Pier Giuseppe Pelicci

European Institute of Oncology, Milan, Italy.

16 When cells get stressed: an integrative view of cellular senescence

Ittai Ben-Porath and Robert A. Weinberg

The Whitehead Institute, Cambridge, Massachusetts, USA.

17 Telomeres, stem cells, senescence, and cancer

Norman E. Sharpless and Ronald A. DePinho

Dana Farber Cancer Institute, Boston, Massachusetts, USA.

18 Bmi1, stem cells, and senescence regulation

In-Kyung Park, Sean J. Morrison, and Michael F. Clarke

University of Michigan, Ann Arbor, Michigan, USA.

19 Cellular senescence in cancer treatment: friend or foe?

Pascal Kahlem, Bernd Dörken, and Clemens A. Schmitt

Max Delbruck Center for Molecular Medicine, Berlin, Germany.

20 Mechanisms for pituitary tumorigenesis: the plastic pituitary

Shlomo Melmed

Cedars-Sinai Medical Center, Los Angeles, California, USA.

21 Melanoma genetics and the development of rational therapeutics

Yakov Chudnovsky, Paul A. Khavari, and Amy E. Adams

Stanford University School of medicine, Stanford, California, USA.

22 Immunopathogenesis and therapy of cutaneous T cell lymphoma

Ellen J. Kim, Stephen Hess, Stephen K. Richardson, Sara Newton, Bernice M. Benoit, Ravi Ubriani, Carmela C. Vittorio, Jacqueline M. Junkins-Hopkins, Maria Wysocka, Alain H. Rook

23 Cancer vaccines: progress reveals new complexities

Zhiya Yu and Nicholas P. Restifo

National Cancer Institute, NIH, Bethesda, Maryland, USA.

PART 3 – IMMUNE SYSTEM and IMMUNE-MEDIATED INJURY

24 IFNs and STATs in innate immunity to microorganisms

Thomas Decker, Silvia Stockinger, Marina Karaghiosoff, Mathias Müller, and Pavel Kovarik

Vienna Biocenter, Vienna, Austria.

25 Molecular aspects of primary immunodeficiencies: lessons from cytokine and

other signaling pathways

Fabio Candotti, Luigi Notarangelo, Roberta Visconti, and John O’Shea

National Human Genome Research Institute, NIH, Bethesda, Maryland, USA.

26 An integrated view of suppressor T cell subsets in immunoregulation

Hong Jiang and Leonard Chess

Columbia University College of Physicians and Surgeons, New York, USA.

27 CD4+ Tregs and immune control

Zoltán Fehérvari and Shimon Sakaguchi

Kyoto University, Kyoto, Japan.

28 Tregs and allergic disease

Douglas S. Robinson, Mark Larché, and Stephen R. Durham

Imperial College, London, Great Britain.

29 Tregs and transplantation tolerance

Patrick T. Walsh, Devon K. Taylor, and Laurence A. Turka

University of Pennsylvania, Philadelphia, Pennsylvania, USA.

30 C-reactive protein: a critical update

Mark Pepys and Gideon Hirschfield

Royal Free and University College Medical School, London, United Kingdom.

31 New insights into atopic dermatitis

Donald Y.M. Leung, Mark Boguniewicz, Michael D. Howell, Ichiro Nomura,

and Qutayba A. Hamid

National Jewish Center, Denver, Colorado, USA.

32 Recent insights into the immunopathogenesis of psoriasis provide

new therapeutic opportunities

Brian J. Nickoloff and Frank O. Nestle

Loyola University Medical Center, Maywood, Illinois, USA.

University of Zurich Medical School, Zurich, Switzerland.

33 Exploiting dendritic cells to improve vaccine efficacy

Ralph M. Steinman and Melissa Pope

Rockefeller University, New York, USA.

PART 4 – INFECTIOUS DISEASES

Clinical Syndromes

34 The enigma of sepsis

Niels C. Riedemann, Ren-Feng Guo, and Peter A. Ward

University of Michigan, Ann Arbor, Michigan, USA.

Gram-positive bacteria in health and disease

35 Antimicrobial resistance: the example of Staphylococcus aureus

Franklin D. Lowy

Columbia University College of Physicians and Surgeons, New York, USA.

36 Bacterial infectious disease control by vaccine development Roy Curtiss, III

Washington University, St. Louis, Missouri, USA

.

37 Development of an improved vaccine for anthrax

Stephen H. Leppla, John B. Robbins, Rachel Schneerson, and Joseph Shiloach

National Institutes of Health, Bethesda, Maryland, USA.

Gram-negative bacteria in health and disease

38 Helicobacter pylori persistence: biology and disease

Martin J. Blaser and John C. Atherton

New York University Medical Center, New York, USA.

39 The emergence of Lyme disease

Allen C. Steere, Jenifer Coburn, and Lisa Glickstein

Tufts University, Boston, Massachusetts, USA.

Bacterial communication

40 The application of biofilm science to the study and control of chronic

bacterial infections

William Costerton, Richard Veeh, Mark Shirtliff, Mark Pasmore,

Christopher Post, and Garth Ehrlich

Montana State University, Montana, USA.

41 Quorum sensing in Staphylococcus infections

Jeremy M. Yarwood and Patrick M. Schlievert

University of Minnesota, Minneapolis, Minnesota, USA.

42 Quorum sensing and biofilm formation in Streptococcal infections

Dennis G. Cvitkovitch, Yung-Hua Li, and Richard P. Ellen

University of Toronto, Toronto, Ontario, Canada.

43 Pharmacological inhibition of quorum sensing for the treatment of chronic bacterial infections

Morten Hentzer and Michael Givskov

Technical University of Denmark, Lyngby, Denmark.

44 Pseudomonas aeruginosa quorum sensing as a potential antimicrobial target 20364

Roger S. Smith and Barbara H. Iglewski

University of Rochester, Rochester, New York, USA.

Protozoal Infections

45 Antimalarial drug resistance

Nicholas J. White

Mahidol University, Bangkok, Thailand.

Parasitic infections

46 Human African trypanosomiasis of the CNS: current issues and challenges

Peter G.E. Kennedy

University of Glasgow, Glasgow, Scotland.

PART 5 –VIRAL DISEASES

47 SARS coronavirus: a new challenge for prevention and therapy

Kathryn Holmes

University of Colorado Health Science Center, Denver, Colorado, USA.

48 Acute HIV revisited: new opportunities for treatment and prevention

Christopher D. Pilcher, Joseph J. Eron Jr., Shannon Galvin, Cynthia Gay, and Myron S. Cohen

University of North Carolina, Chapel Hill, North Carolina, USA.

49 Strategies for an HIV vaccine

Norman L. Letvin

Harvard University, Boston, Massachusetts, USA.

50 Dengue: defining protective versus pathologic immunity

Alan L. Rothman

University of Massachusetts, Worcester, Massachusetts USA.

51 West Nile virus: a growing concern?

L. Hannah Gould and Erol Fikrig

Yale University School of Medicine, New Haven, Connecticut, USA.

52 Progress on new vaccine strategies against chronic viral infections Jay A. Berzkofsky, Jeffrey D. Ahlers, John Janik, John Morris, SangKon Oh, Masaki Terabe,

and Igor M. Belyakov

National Cancer Institute, NIH, Bethesda, Maryland, USA.

53 Parainfluenza virus entry into cells as a target for interrupting

childhood respiratory disease

Anne Moscona

Mount Sinai School of Medicine, New York, USA.

54 Influenza vaccines: present and future Peter Palese and Adolfo García-Sastre

Mount Sinai School of Medicine, New York, USA.

55 Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics

Brian R. Murphy and Peter L. Collins

National Institute for Allergy and Infectious diseases, NIH, Bethesda, Maryland, USA.

56 Herpes simplex viruses: is a vaccine tenable?

Richard J. Whitley and Bernard Roizman

University of Chicago, Chicago, Illinois, USA.

57 Prophylactic human papillomavirus vaccines

Douglas R. Lowy and John T. Schiller

National Cancer Institute, NIH, Bethesda, Maryland, USA.

PART 6 – RESPIRATORY SYSTEM

58 Disorders of lung matrix remodeling

Harold A. Chapman

University of California, San Francisco, California, USA.

59 New insights into the pathogenesis of asthma

Jack A. Elias, Chun Geun Lee, Tao Zheng, Bing Ma, Robert J. Homer, and Zhou Zhu

Yale University School of Medicine, New Haven, Connecticut, USA.

60 JAK-STAT signaling in asthma

Alessandra B. Pernis and Paul B. Rothman

Columbia University College of Physicians and Surgeons, New York, USA.

61 Rescuing protein conformation: prospects for pharmacological therapy

in cystic fibrosis

Marina S. Gelman and Ron R. Kopito

Stanford University Medical Center, Stanford, California, USA.

62 Epithelial-mesenchymal transition and its implications for fibrosis

Raghu Kalluri and Eric G. Neilson

Harvard University, Cambridge, Massachusetts, USA.

PART 7 – CARDIOVASCULAR SYSTEM

63 Oxygen, oxidative stress, hypoxia, and heart failure

Frank J. Giordano

Yale University, New Haven, Connecticut, USA.

64 NO/redox disequilibrium in the failing heart and cardiovascular system

Joshua M. Hare and Jonathan S. Stamler

Duke University Medical Center, Durham, North Carolina, USA.

65 Genetic causes of human heart failure

Hiroyuki Morita, Jonathan Seidman, and Christine E. Seidman

Harvard University, Boston, Massachusetts, USA.

66 Protein kinase cascade in the regulation of cardiac hypertrophy

Gerald W. Dorn II and Thomas Force

University of Cincinnati, Cincinnati, Ohio, USA.

67 Toward transcriptional therapies for the failing heart: chemical screens

to modulate genes

Timothy A. McKinsey and Eric N. Olson

University of Texas Southwestern Medical Center, Dallas, Texas, USA.

68 Mitochondrial energy metabolism in heart failure: a question of balance

Janice M. Huss and Daniel P. Kelly

Washington University, St. Louis, Missouri, USA.

69 Death begets heart failure

Roger S.-Y. Foo, Kartik Mani, and Richard N. Kitsis

Albert Einstein College of Medicine, New York, USA.

70 Unchain my heart: the scientific foundations of cardiac repair

Stefanie Dimmeler, Andreas M. Zeiher, and Michael D. Schneider

University of Frankfurt Frankfurt, Germany

Baylor College of Medicine, Houston, Texas, USA.

71 Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities

Garret A. Fitzgerald

University of Pennsylvania, Philadelphia, Pennsylvania, USA.

72 Sex is a potent modifier of the cardiovascular system

Leslie Leinwand

University of Colorado, Boulder, Colorado, USA.

Vascular Diseases

73 Cholesterol in health and disease

Ira Tabas

Columbia University College of Physicians and Surgeons, New York, USA.

74 Cholesterol, lipid rafts, and disease

Kai Simons and Robert Ehehalt

Max Planck Instittue of Molecular medicine, Dresden, Germany.

75 Malformation syndromes due to inborn errors of cholesterol synthesis

Forbes D. Porter

National Institutes of Health, Bethesda, Maryland, USA.

76 Intracellular cholesterol transport

Frederick R. Maxfield and Daniel Wüstner

Cornel University Medical College, New York, USA.

77 Regulation and mechanisms of macrophage cholesterol efflux

Alan R. Tall, Philippe Costet, and Nan Wang

Columbia University College of Physicians and Surgeons, New York, USA.

78 Consequences of cellular cholesterol accumulation: basic concepts and physiological implications

Ira Tabas

Columbia University College of Physicians and Surgeons, New York, USA.

79 Monogenic hypercholesterolemia: new insights in pathogenesis and treatment

Daniel J. Rader, Jonathan Cohen, and Helen H. Hobbs

University of Pennsylvania, Philadelphia, Pennsylvania, USA.

University of Texas Southwestern Medical Center, Dallas, Texas, USA.

80 Isoprenoids as mediators of the biological effects of statins

James K. Liao

Harvard University, Cambridge, Massachusetts, USA.

Disorders of rhythm

81 The channelopathies: novel insights into molecular and genetic

mechanisms of human disease

Robert Kass

Columbia University Colleges of Physicians and Surgeons, New York, USA.

82 Mechanisms of sudden cardiac death

Michael Rubart and Douglas P. Zipes

Krannert Institute of Cardiology, Indianapolis, Indiana, USA.

83 Long QT syndrome: from channels to cardiac arrhythmias

Arthur J. Moss and Robert Kass

University of Rochester Medical Center, Rochester, New York, USA.

84 Genetics of acquired long QT syndrome

Dan M. Roden

Vanderbilt University, Nashville, Tennessee, USA.

85 Muscle channelopathies and critical points in functional and genetic studies

Karin Jurkat-Rott and Frank Lehmann-Horn

Ulm University, Ulm, Germany

86 Inherited disorders of voltage-gated sodium channels

Alfred L. George, Jr.

Vanderbilt University, Nashville, Tennessee, USA.

87 Cardiac and skeletal muscle disorders caused by mutations in the

intracellular Ca2+-release channels

Silvia G. Priori and Carlo Napolitano

University of Pavia, Pavia, Italy.

88 Chloride channel diseases resulting from impaired transepithelial

transport or vesicular function

Thomas J. Jentsch, Tanja Maritzen, and Anselm A. Zdebik

PART 8 – HEMATOLOGY

89 Megakaryocyte biology and related disorders

Liyan Pang, Mitchell J. Weiss, and Mortimer Poncz

Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

90 The molecular mechanisms that control thrombopoiesis

Kenneth Kaushansky

University of California, San Diego, California, USA.

91 Thrombus formation in vivo

Bruce Furie and Barbara C. Furie

Beth Israel Deaconess Medical Center, Harvard University. Boston, Massachusetts, USA.

92 Platelet genomics and proteomics in human health and disease

Ian C. Macauley, Philippa Carr, Arief Gusnanto, Willem H. Ouwehand,

Des Fitzgerald, and Nicholas A. Watkins

University College Dublin, Dublin, Ireland.

93 The biogenesis of platelets from megakaryocyte proplatelets

Sunita R. Patel, John H. Hartwig, and Joseph Italiano

Harvard University, Cambridge, Massachusetts, USA.

94 Platelets in inflammation and atherogenesis

Meinrad Gawaz, harald Langer, and Andreas E. May

Munich Technical University, Munich, Germany.

95 Structure and function of the platelet integrin (IIb(3

Joel S. Bennett

University of Pennsylvania, Philadelphia, USA.

96 Minding the gaps to promote thrombus growth and stability

Lawrence F. Brass, Li Zhu, and Timothy J. Stalker

University of Pennsylvania, Philadelphia, Pennsylvania, USA.

97 Untying the Gordian knot: policies, practices, and ethical issues related to

banking of umbilical cord blood

Joanne Kurtzberg

Duke University, Durham, North Carolina, USA.

PART 9 – GASTROINTESTINAL SYSTEM

98 Intestinal ion transport and the pathophysiology of diarrhea

Michael Field

Columbia University Colleges of Physicians and Surgeons, New York, USA.

99 Molecular mediators of hepatic steatosis and liver injury

Jeffrey D. Browning and Jay D. Horton

University of Texas Southwestern Medical Center, Dallas, Texas, USA.

100 Liver fibrosis

Ramón Bataller and David A. Brenner

Columbia University Colleges of Physicians and Surgeons, New York, USA.

101 SREBPs: activators of the complete program of cholesterol and

fatty acid synthesis in the liver

Jay D. Horton, Joseph L. Goldstein, and Michael S. Brown

University of Texas Southwestern Medical Center, Dallas, Texas, USA.

PART 10 – ENDOCRINOLOGY AND METABOLISM

102 Genetic epidemiology of diabetes

M. Alan. Permutt, Jonathan Wasson, and Nancy Cox

Washington University. St. Louis, USA.

103 ATP-sensitive potassium channelopathies: focus on insulin secretion

Frances M. Ashcroft

University of Oxford, Oxford, Great Britain.

104 Gestational diabetes mellitus

Thomas A. Buchanan and Anny H. Xiang

University of Southern California, Los Angeles, California, USA.

105 Regeneration of the pancreatic ( cell

Massimo Trucco

University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

106 Challenges facing islet transplantation for the treatment of

type 1 diabetes mellitus

Kristina I. Rother and David M. Harlan

National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland, USA.

107 How does blood glucose control with insulin save lives in intensive care?

Greet Van den Berghe

Katholieke University Lueven, Belgium.

108 Thyrotropin receptor–associated diseases: from adenomata to Graves’ disease

Terry F. Davies, Takao Ando, Reigh-Yi Lin, Yaron Tomer and Rauf Latif

Mount Sinai School of Medicine, New York, USA.

109 Inflammation, stress, and diabetes

Kathryn E. Wellen and Gökhan S. Hotamisligil

Harvard School of Public Health, Boston, Massachusetts, USA.

110 Adiponectin and adiponectin receptors in insulin resistance,

diabetes, and the metabolic syndrome

Takashi Kadowaki, Toshimasa Yamauchi, Naoto Kubota, Kazuo Hara, Kohjiro Ueki, and Kazuyuki Tobe

University of Tokyo and National Institute of Health and Nutrition, Tokyo, Japan.

111 The role of cholesterol efflux in regulating the fertilization potential of mammalian spermatozoa

Alexander J. Travis and Gregory S. Kopf

Wyeth, Philadelphia, Pennsylvania, USA.

112 Trophoblast differentiation during embryo implantation and formation of

the maternal-fetal interface

Susan Fisher

University of Califronia, San Francisco, California, USA.

PART 11 – KIDNEY AND URINARY TRACT

113 Acute renal failure: definitions, diagnosis, pathogenesis, and therapy R.W. Schrier, W. Wang, B. Poole, and A. Mitra

University of Colorado, Denver, Colorado, USA.

114 Kidney stone disease

Fredric L. Coe, Andrew Evan, and Elaine Worcester

University of Chicago, Chicago, Illinois, USA.

115 Salt handling and hypertension

Kevin M. O’Shaughnessy and Fiona E. Karet

Cambridge Institute of Medical Research, Cambridge, England, Great Britain.

PART 12 – BONE AND MINERAL METABOLISM

116 Pathogenesis of osteoporosis: concepts, conflicts, and prospects

Lawrence G. Raisz

University of Connecticut, Farmington, Connecticut, USA.

117 Paget disease of bone

G. David Roodman and Jolene J. Windle

University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

118 Estrogen deficiency and bone loss: an inflammatory tale

M. Neale Weitzmann and Roberto Pacifici

Emory University, Atlanta, Georgia, USA.

119 Regulation of bone mass by Wnt signaling

Venkatesh Krishnan, Henry U. Bryant, and Ormond A. MacDougald

Lily Research laboratories, Indianapolis, Indiana, USA

Univeristy of Michigan, Ann Arbor, Michigan, USA.

PART 13 – NEUROLOGIC DISORDERS

120 VEGF: A critical player in neurodegeneration

Erik Strorkebaum and Peter Carmeliet

Katholieke University Lueven, Belgium.

121 Neurogenesis and brain injury: managing a renewable source for repair

Daniel Peterson

Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, USA.

122 Oxidative stress, cell cycle, and neurodegeneration

Jeffrey A. Klein and Susan L. Ackerman

The Jackson Laboratory, Bar Harbor, Maine, USA.

123 Neuronal degeneration and mitochondrial dysfunction

Eric A. Schon and Giovanni Manfredi

Columbia University Colleges of Physicians and Surgeons, New York, USA.

124 The role of cerebral A( accumulation in common forms of Alzheimer disease

Sam Gandy

Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

125 Alzheimer disease therapy: Can the amyloid cascade be halted?

Todd E. Golde

Mayo Clinic, Jacksonville, Florida.

126 Diagnosis and treatment of Parkinson disease: molecules to medicine

Joseph M. Savitt, Valina L. Dawson, and Ted M. Dawson

Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

127 Huntingtin in health and disease

Anne B. Young

Massachusetts General Hospital, Boston, Massachusetts, USA.

128 Programmed cell death in amyotrophic lateral sclerosis

Christelle Guégan and Serge Przedborski

Columbia University College of Physicians and Surgeons, New York, USA.

129 Multiple sclerosis

David A. Hafler

Brigham and Women’s Hospital, Harvard University, Boston, Massachusetts, USA.

130 Progress and problems in the biology, diagnostics, and therapeutics of prion diseases

Adriano Aguzzi

University Hospital of Zurich, Zurich, Switzerland.

131 The genetic epidemiology of neurodegenerative disease

Lars Bertrum and Rudolf Tanzi

Massachusetts General Hospital, Harvard University, Charlestown, Massachusetts, USA.

132 Sodium channels in epilepsy and other neurological disorders

Miriam Meislerand Jennifer Kearney

University of Michigan, Ann Arbor, Michigan, USA.

133 Finding schizophrenia genes

George Kirov, Michael O’Donovan, and Michael Owen

University of Wales, Cardiff, Great Britain.

134 The addicted human brain: insights from imaging studies

Nora D. Volkow, Joanna S. Fowler, and Gene-Jack Wang

Brookhaven National Laboratory, Upton, New York, USA.

PART 14 – GENETICS AND DISEASE

135 Mapping the new frontier – complex genetic disorders

Richard Mayeux

Columbia University Colleges of Physicians and Surgeons, New York, USA.

136 Mapping quantitative trait loci in humans: achievements and limitations

Partha Majumder and Saurabh Ghosh

Indian Statistical Institute, Kolkata, India.

137 Linkage disequilibrium maps and association mapping

Newtown Morton

University of Southampton, Southampton, Great Britain.

138 Genetic counselors: translating genomic science into clinical practice

Robin L. Bennett, Heather L. Hampel, Jessica B. Mandell, and Joan H. Marks

University of Washington, Seattle, Washington, USA.

139 Genetic counseling throughout the life cycle

Leslie J. Ciarleglio, Robin L. Bennett, Jennifer Williamson, Jessica B. Mandell,

and Joan H. Marks

University of Washington, Seattle, Washington, USA.

Columbia University College of Physicians and Surgeons, New York, USA.

140 Payment of clinical research subjects

Christine Grady

Clinical Bioethics, National Institutes of Health, Bethesda, Maryland, USA.

141 Embryonic death and the creation of human embryonic stem cells

Donald W. Landry and Howard A. Zucker

Columbia University Colleges of Physicians and Surgeons, New York, USA

142 Stem cells: science, policy, and ethics

Gerald D. Fischbach and Ruth L. Fischbach

Columbia University Colleges of Physicians and Surgeons, New York, USA.

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download